Background-The degree to which cytochrome P450 (CYP) 2C19 genotype influences the effectiveness of clopidogrel remains uncertain because of considerable heterogeneity in results between studies and potential publication bias. Clopidogrel indication and ethnic population have been proposed to influence the effect of CYP2C19 genotype. Methods and Results-A systematic review was undertaken up to 14 November 2013. Meta-analysis of the CYP2C19 genotype effect was stratified by the predominant clopidogrel indication (percutaneous coronary intervention [PCI] versus non-PCI) and ethnic population (white versus Asian) of each primary study. The primary analysis was restricted to studies with ≥500 participants, which comprised 24 studies and a total of 36 076 participants. The association between carriage of ≥1 CYP2C19 loss-of-function (LoF) allele and major cardiovascular outcomes differed significantly (P<0.001) between studies of whites not undergoing PCI (relative risk 0.99 [95% confidence interval, 0.84-1.17]; n=7043), whites undergoing PCI (1.20 [1.10-1.31]; n=19,016), and Asians undergoing PCI (1.91 [1.61-2.27]; n=10,017). Similar differences were identified in secondary analyses of 2 CYP2C19 LoF alleles, stent thrombosis outcomes, and studies with ≥200 participants. Minimal heterogeneity was apparent between studies of Asian populations. Conclusions-The reported association between CYP2C19 LoF allele carriage and major cardiovascular outcomes differs based on the ethnic population of the study and, to a lesser extent, the clopidogrel indication. This is potentially of major importance given that over 50% of Asians carry ≥1 CYP2C19 LoF alleles. (Circ Cardiovasc Genet. 2014;7:895-902.)
I t is well recognized that there is substantial interindividual variability in response to clopidogrel therapy and that carriage of a cytochrome P450 (CYP) 2C19 loss-of-function (LoF) allele may partially explain this variability. 1 Although the relationship between risk of adverse cardiovascular outcomes and CYP2C19 LoF allele carriage in users of clopidogrel has been extensively researched, important questions still remain regarding the degree to which carriage of CYP2C19 LoF alleles actually increases the risk of adverse cardiovascular outcomes, what is causing the significant between-study heterogeneity in effect size, and whether publication bias has significantly inflated the effect sizes estimated by prior meta-analyses. [2] [3] [4] [5] 
Clinical Perspective on p 902
For individuals using clopidogrel, the largest and most consistently reported association between carriage of a CYP2C19 LoF allele and a clinical outcome is for stent thrombosis. 5, 6 Consequently, it has been proposed that the effect size of CYP2C19 LoF allele carriage on adverse cardiovascular outcomes for individuals using clopidogrel may be indication-dependent-specifically, that the effect size is greatest for use of clopidogrel after percutaneous coronary intervention (PCI). 1, 4, 7, 8 In 2010, Mega et al 6 published a meta-analysis predominantly focused on clopidogrel use after PCI, in which a relatively large effect size of CYP2C19 LoF allele carriage on adverse cardiovascular outcomes was reported. It has been speculated that the smaller effect sizes and significant heterogeneity reported in more recent meta-analyses may have resulted from the inclusion of studies in which clopidogrel is used for other indications (eg, stable coronary artery disease, atrial fibrillation, and medically managed acute coronary syndrome [ACS]). 4, 8 However, no studies to date have specifically focused on assessing the evidence for this hypothesis.
There are almost certainly several (as yet undefined) genetic and nongenetic factors that contribute to the variability in clopidogrel effectiveness. 9 Patient ethnicity and geographical variation may be used as surrogates, at least in part, for such differences in lieu of a more formal identification of the specific factors involved. To this end, many studies have recently been published focusing on the association between adverse cardiovascular outcomes and CYP2C19 LoF carriage in Asian populations, and it has been suggested that ethnicity may contribute to heterogeneity between study results as Asian populations have a substantially greater prevalence of the CYP2C19 LoF allele. 10 This meta-analysis primarily aimed to evaluate the evidence supporting the hypothesis that the effect size associated with CYP2C19 LoF allele carriage on the risk of major adverse cardiovascular outcomes differs between use of clopidogrel for PCI compared with other clopidogrel indications and between studies of white and Asian populations.
Methods

Inclusion Criteria
The prespecified inclusion criteria for the primary analysis comprised cohort studies and substudies of randomized controlled trials with ≥500 participants who used clopidogrel, were genotyped for CYP2C19 LoF alleles (minimally *2), and reported follow up for major adverse cardiovascular outcomes (ie, death/cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke).
The rationale for restriction to studies of ≥500 participants in the primary analysis was based on the potential for significant publication bias, which has been highlighted in recent meta-analyses of CYP2C19 LoF alleles. 5, 11 A sample size of 500 participants was arbitrarily chosen on the basis that a study of such a size is likely to be published or presented at a conference irrespective of its results. This sample size threshold has been used in prior analyses, 3, 11 and it was specified before reviewing results from studies or undertaking any meta-analysis to compare indication-specific subgroups. In addition, a prespecified sensitivity analysis was undertaken using a lower threshold of 200 participants to assess whether the findings were dependent on the threshold for inclusion.
The prespecified preferred definition of adverse cardiovascular outcomes was the composite of cardiovascular death (or alternatively all-cause death), nonfatal myocardial infarction, or nonfatal stroke. If this event definition was not reported and there were alternative outcomes reported, the outcome that included the greatest number of death, myocardial infarction, and stroke outcomes without inclusion of other outcomes was utilized.
Search Strategy
Embase, Medline, and Web of Science (up to 14 November 2013) were searched for the following terms: clopidogrel OR Plavix OR Iscover AND cytochrome P450 2C19 OR CYP2C19 OR CYP 2C19 OR 2C19 AND clinical study OR clinical trial OR controlled study OR cohort study. No restrictions were placed on the search, and relevant MeSH (Medline) or Emtree (Embase) terms were used where possible. Initially, duplicate titles were removed and then the title of the articles was scanned to determine if the article was irrelevant. The abstract of all remaining articles were then retrieved and reviewed, and irrelevant articles were discarded. Of the remaining articles, full-text manuscripts were obtained, and those that fulfilled the inclusion criteria (for the main and sensitivity analysis) were documented. After identification of relevant articles, the Pharmacogenomics Knowledgebase (http://www. pharmgkb.org/, accessed 20 November 2014), reference list of the articles that were identified as relevant and prior meta-analyses, 5, 6, 11, 12 were hand-searched to identify any additional articles that were missed with the search strategy. Studies reported in conference abstracts and published in languages other than English were included if sufficient information was available in the (English) abstract and the associated tables or figures. The search strategy was undertaken independently by 2 investigators (A. Rowland and M. Wiese) with any discrepancies resolved by the other investigators (M. Sorich and R. McKinnon).
Data Extraction
Data extracted from eligible studies included study characteristics in terms of ethnicity (country or geographical locations of investigation, ethnicity of study participants) and design; participants characteristics in terms of baseline disease diagnosis and intervention, demographics, and cardiovascular risk factors; and outcome measures. General indicators of the quality of epidemiological studies and genetic association studies included loss to follow-up, sources of funding, blinding of clinical outcome assessors to patients' genetic information, and reliability and validity of genotype assessment (eg, Hardy-Weinberg equilibrium, call rate).
Statistical Analysis
The relative risk (RR; specifically the risk ratio) was primarily used to represent the association between carriage of 1 or 2 CYP2C19 LoF alleles and adverse cardiovascular outcomes. The carriage of 1 or 2 CYP2C19 LoF alleles (ie, dominant genetic model) was prespecified as the genotype grouping for the primary analysis on the basis that this is the most commonly reported grouping of CYP2C19 LoF alleles and therefore minimizes potential for selective reporting bias. The RR of adverse cardiovascular outcomes associated with carriage of 2 CYP2C19 LoF alleles (versus no CYP2C19 LoF alleles) was a prespecified secondary analysis. The RR for each study was calculated based on the number of individuals reported to have an adverse cardiovascular outcome and the number of individuals at risk in each genotype group. If the number of events and participants were not reported, the hazard ratio was used to estimate the RR if available.
On the basis of prior studies and commentaries, 4, 7, 8, 10 the primary analysis comparisons for clopidogrel indication and ethnic population were prespecified to be PCI versus non-PCI and white versus Asian, respectively. The meta-analysis was stratified on the basis of both the predominant ethnic population and clopidogrel indication of each study, resulting in 4 potential subgroups: white, non-PCI; white, PCI; Asian, non-PCI; and Asian, PCI. Strata-specific summary estimates were reported using both a fixed-effect model based on the Mantel-Haenszel method and a random-effects model based on the DerSimonian-Laird method. The rationale is that the statistical model used has varied between previous meta-analyses and that this has likely contributed to differences in meta-analysis results because of heterogeneity in effect size between primary studies and small study effects (potential publication bias). 2 A fixed-effect statistical model assumes that there is 1 true effect size that underlies all the studies in the analysis. In contrast, a randomeffects model allows for the true effect size to differ from study to study.
For studies that included a mix of PCI and non-PCI participants, estimates that were specific to (or enriched for) PCI and non-PCI groups were preferentially used if available. In addition, to better account for a small number of studies with a mix of PCI and non-PCI participants, a meta-regression was also undertaken using the proportion of participants that underwent PCI as a continuous variable. A mixed-effects model was used to assess whether the RR was associated with clopidogrel indication and ethnic population. The statistical significance of heterogeneity between studies and subgroups was assessed using the Q test based on the χ 2 distribution. The R 2 index was used to estimate the proportion of true variance in the RR that was explained by the study covariates.
Post hoc analyses were undertaken to further explore differences between clopidogrel indications (ACS versus no ACS), ethnic populations (Chinese versus Korean), CYP2C19 LoF alleles genotyped (*2 versus both *2 and *3), and clinical outcomes (stent thrombosis and bleeding).
Comparisons not prespecified were reported as being post hoc. All statistical tests were 2-sided and a P value of <0.05 was considered statistically significant. Statistical analyses were performed with R version 3.0.
Results
Overview of Studies
Twenty-four studies across 23 publications comprising a total of 36 076 participants with known CYP2C19 LoF status and relevant cardiovascular outcomes were included in the primary analysis ( Figure 1 ; Table I in the Data Supplement); of these, 8 studies comprising 10 017 participants were from Asian populations, whereas 16 studies comprising 26 059 participants were from white populations. 6, No major discrepancies were observed in the assessment 23 all studies reported normal Hardy-Weinberg equilibrium (P>0.05).
28.4% of participants in studies of white populations carried 1 or 2 CYP2C19 LoF alleles compared with 53.9% of participants in studies of Asian populations. Of the studies reporting on carriage of 2 CYP2C19 LoF alleles, the average prevalence of carriage of 2 CYP2C19 LoF alleles was 2.4% and 11.2% for studies with white and Asian populations, respectively.
Although there were considerable difference in terms of the prevalence of CYP2C9 LoF alleles, the 2 study populations were comparatively homogenous in terms of demographics; the mean participant ages ranged from 60.1 to 70.8 years in white and from 58.9 to 70.8 years in Asian studies, mean body mass index ranged from 26.1 to 30.3 in white studies and from 24.5 to 32.2 in Asian studies, whereas the proportion of males ranged from 54.4% to 78.3% in white studies and from 59% to 83.5% in Asian studies. The 2 populations were also similar in terms of the proportion of study participants with CVD risk factors, although there was a minor trend toward higher rates of smoking, but lower rates of hypertension and dyslipidaemia, in Asian studies.
Statistical Significance of Differences in Genetic Effect Size Between Subgroups
The RR associated with CYP2C19 LoF allele carriage differed significantly between subgroups of studies on the basis of predominant ethnic population and clopidogrel indication of the study participants ( Figure 2 ; P<0.001). Approximately 74% of the true heterogeneity between studies was explained by these 2 study characteristics (R 2 =0.74). Based on meta-regression analysis, both the predominant ethnic population and the proportion of participants undergoing PCI helped explain the heterogeneity in RR estimates between studies (P<0.001 and P=0.043, respectively).
Association Between CYP2C19 LoF Allele Carriage and Cardiovascular Outcomes for Each Subgroup
Four studies and 7043 participants contributed to the white, non-PCI subgroup in which no association between CYP2C19 LoF and adverse cardiovascular outcomes was evident (RR 0.99 [95% confidence interval [CI], 0.84-1.17]; Figure 2 ). [13] [14] [15] [16] In contrast, a modest association (RR 1.20 [95% CI, 1.10-1.31]; Figure 2 ) was apparent based on 13 studies of 19 016 participants in the white, PCI subgroup. 14, 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Moderate heterogeneity was evident between the white, PCI studies (I 2 =50%, P=0.02; Figure 2 ).
There were no studies identified that studied the use of clopidogrel in Asian participants for an indication other than PCI. Based on 8 studies of 10 017 participants in the Asian, PCI subgroup, there was a large association between carriage of a CYP2C19 LoF allele and adverse Cardiovascular outcomes (RR 1.91 [95% CI, 1.61-2.27]; Figure 2 ). [29] [30] [31] [32] [33] [34] [35] [36] No heterogeneity was evident for these studies.
Sensitivity Analyses
Differences between ethnic groups were consistent across sensitivity analyses for meta-analysis methods, study size inclusion criterion, CYP2C19 allele grouping, and cardiovascular outcome. Fixed-effect and random-effects meta-analysis estimates consistently demonstrated a difference between ethnic populations. Visual inspection and regression tests did not indicate significant funnel plot asymmetry. Specifically, Egger's linear regression test was not significant for the Asian, PCI and white, PCI subgroups (P=0.45 and P=0.75, respectively), and the trim-and-fill fixed-effect RR estimates were 1.88 [1.58-2.22] and 1.19 [1.09-1.29], respectively.
Results were essentially unchanged in a sensitivity analysis based on all studies with a sample size >200, which included an additional 10 studies and 3057 participants (Figure I in the Notably, the effect was most pronounced for the comparison of 2 LoF alleles versus no LoF alleles: RR of 3.01 for the Asian, PCI subgroup compared with 1.56 for the white, PCI subgroup.
A sensitivity analysis based on stent thrombosis as the cardiovascular outcome also demonstrated similar subgroup trends. Carriage of a CYP2C19 LoF allele was associated with an increased risk of stent thrombosis for studies of both Asian and white participants ( Figure 3 ). 47-52 However, the RR was larger for studies undertaken in Asian populations (4.88 [95% CI, 3.05-7.80]) compared with studies in predominantly white populations (1.73 [95% CI, 1.47-2.05]).
Exploratory Analyses
Visual inspection of study demographics indicated modest trends toward a higher proportion of smokers, but lower proportion of participants with dyslipidemia and hypertension and lower body mass index in Asian studies. Only differences in proportion with dyslipidemia were statistically significant (P=0.005). Metaregression indicated that the average age and body mass index, proportion that are smokers, or have diabetes mellitus, hypertension, and dyslipidaemia in each study were not significantly associated with the effect size of CYP2C19 LoF carriage reported for the study. Additionally, including these variables along with ethnicity in a meta-regression did not substantively alter the importance of the ethnic population variable (data not shown).
No significant difference in the CYP2C19 LoF allele effect size was evident for individuals undergoing PCI for ACS compared with elective PCI (data not shown). Individuals with a CYP2C19 LoF allele that were using clopidogrel for medically managed ACS (ie, without PCI) did not seem to be at increased risk of adverse cardiovascular outcomes (RR 0.89 [95% CI, 0.72-1.10]; n=4217). 13, 15 There was no indication of a difference in RR reported by studies with Korean and Chinese participants Pare 2010 (ACTIVE A) 13 Wallentin 2010 (Medical) 14, 15 Bhatt 2012 16 Pare 2010 (CURE) 13 Delaney 2012 17 Harmsze 2011 18 Giusti 2009 19 Trenk 2008 20 Tiroch 2010 21 Marcucci 2012 22 Anderson 2009 23 Verschuren 2013 24 Mega 2009 
Discussion
The results presented here indicate that carriage of a CYP2C19 LoF allele is likely to increase the risk of adverse cardiovascular outcomes only when clopidogrel is used for PCI. Furthermore, the effect associated with the CYP2C19 LoF allele differs markedly depending on the ethnic population of the study. Studies with predominantly white participants using clopidogrel for PCI indicate that CYP2C19 LoF allele carriage is associated with a modest increase in the risk of adverse cardiovascular outcomes, and there is moderate unexplained heterogeneity between studies. However, studies of Asian (mainly Chinese and Korean) populations using clopidogrel for PCI indicate that carriage of a CYP2C19 LoF allele is associated with a consistent and marked increase in the risk of adverse cardiovascular outcomes. Analysis of stent thrombosis outcomes was supportive of differences in the effect size of CYP2C19 LoF allele carriage between Asian (RR of 4.88) and white populations (RR of 1.73).
Heterogeneity in study results and risk of publication bias are major issues highlighted in prior studies, which have made the clinical utility of genotyping CYP2C19 difficult to assess. The strength of this study is the specific focus on assessing these proposed sources of heterogeneity, while minimizing the effect of potential publication bias. By focusing on the joint effects of clopidogrel indication and ethnic population in studies least likely to have publication bias (>500 participants), the effect of these factors can be more reliably evaluated. A limitation of this study is that it is not possible to establish if clopidogrel indication or ethnicity was causally responsible for the observed differences in effect size according to CYP2C19 LoF allele. For instance, it may be that there are systematic differences in study design, patient characteristics, concomitant therapy, clopidogrel use, or healthcare systems between the predominantly Asian and white studies that are actually responsible.
Although indication-specific differences in the effect of CYP2C19 LoF carriage have been proposed on multiple occasions, 1, 4, [6] [7] [8] this is the first meta-analysis that has primarily aimed to assess the evidence supporting this hypothesis in any detail, while controlling for other factors (ethnic population and study size). The potential for differences between Asian and white populations has been raised by a prior study, but findings were limited by the preliminary nature of the data available and the lack of control for differences in clopidogrel indication and small study effects. 10 Over the past 2 years, there has been considerable expansion of the published data informing the effect of the CYP2C19 genotype in Asian populations. The current analysis is based on over 10 000 participants enrolled in large . 5 This study also provides an important update on the effect of CYP2C19 LoF allele carriage for whites undergoing PCI. Although there are larger and more recent meta-analyses, the 2010 meta-analysis by Mega and colleagues continues to be influential because of its focus on a population undergoing PCI. 1, 2, 6 The RR estimated for whites undergoing PCI is considerably smaller (1.20 [95% CI, 1.10-1.31]) than that reported by Mega et al 6 (hazard ratio of 1.57 [95% CI, 1.13-2.16]). The current analysis includes data from the 6 largest studies (93% of the participants) included in the 2010 metaanalysis by Mega and colleagues plus an additional 7 large studies focusing on clopidogrel use for PCI in a white population that were published between 2010 and 2013. 14, 17, 18, 21, 22, 24, 26 Current guidance by the Clinical Pharmacogenetics Implementation Consortium suggests that the effect of CYP2C19 LoF allele carriage is likely greatest for individuals undergoing PCI for ACS. 1 The current study supports the assertion that the effect of CYP2C19 LoF allele carriage is likely greater for individuals using clopidogrel that are undergoing PCI. The updated estimate for the white, PCI subgroup and the confirmation of a more marked effect for the Asian, PCI subgroup will be of value to inform subsequent updates to the guidance.
Additionally, the FDA black box warning for clopidogrel (Plavix ® ) states that poor metabolizers (individuals with 2 CYP2C19 LoF alleles) treated with Plavix ® at recommended doses exhibit higher cardiovascular event rates after ACS or PCI than patients with normal CYP2C19 function. 55 That poor metabolizers (individuals with 2 CYP2C19 LoF alleles) are at greatest risk has been previously established. 6 This study highlights that evaluation of the effect of CYP2C19 LoF alleles for individuals with medically managed ACS (ie, without PCI) is restricted to 2 large studies-the CURE genetic substudy (n=2530) 13 and the medically managed subset of the PLATO genetic substudy (n=1687) 15 which consistently indicate that carriers of 1 or 2 CYP2C19 LoF alleles are unlikely to have increased risk of cardiovascular outcomes. Only the CURE study reported the association between carriage of 2 CYP2C19 LoF alleles and cardiovascular outcomes, and no indication of increased risk was apparent. 13 The results presented here indicate a noteworthy association between CYP2C19 LoF allele carriage and cardiovascular outcomes for individuals studied in China and Korea. A single smaller study in a Japanese population also reported a marked association with CYP2C19 LoF carriage, 42 suggesting that the enhanced effect size may be consistent across various Asian regions. A larger effect size of CYP2C19 LoF allele carriage in Asian populations has major implications, given that over 50% of Asians have carriage of 1 or 2 CYP2C19 LoF alleles compared with ≈28% of whites. We have not assessed the CYP2C19*17 (gain-of-function) allele in this study as the LoF alleles are of greatest clinical interest and there is substantially less data for the *17 allele, which would make it difficult to evaluate sources of heterogeneity. Additionally, ethnic differences in the *17 allele effect are unlikely to be of significant clinical relevance because of the low prevalence of the allele in Asian populations. 31, 36 Although the difference in results between ethnic populations is clear, the underlying explanation for the difference is not. One potential explanation is that the primary analysis is based on the pooling of individuals who carry either 1 LoF allele or 2 LoF alleles and that the carriage of 2 LoF alleles likely imparts a greater risk of adverse cardiovascular outcomes than carriage of 1 LoF allele. Thus, some of the genotype effect size differences between ethnic populations observed in the primary analysis may be because there is a different ratio of individuals with 1 LoF allele versus 2 LoF alleles for the 2 ethnicities: ≈21% of Asian LoF allele carriers will actually carry 2 LoF alleles, whereas only 8% of white LoF allele carriers carry 2 LoF alleles. However, this is unlikely to explain the majority of the difference observed because the analysis restricted to carriage of 2 LoF alleles (versus no LoF alleles) also resulted in a substantially larger effect size in studies in Asian compared with white populations (RR 3.01 versus 1.56; Figure 3 ). Another ethnic difference is that Asians have a substantially lower prevalence of the CYP2C19*17 (gain-of-function) allele compared with whites. 13, 31, 36 However, this is also unlikely to explain the differences observed because this would actually favor a larger difference for whites between carriers of 2 LoF alleles and noncarriers of an LoF allele (some of whom carry the CYP2C19*17 allele and are thus ultrarapid metabolizers).
Differences in smoking status, 56,57 age, 9 and body weight 9 have been associated with clopidogrel efficacy. As both seem to differ somewhat between the white and Asian studies, it is possible that these characteristics contribute to the ethnic population differences observed, although how these variables interact with and modulate the effect of CYP2C19 LoF allele carriage is unclear. Although exploratory meta-regression analyses suggest that smoking status and body mass index do not significantly influence the effect size of CYP2C19 LoF carriage, meta-regression of aggregated patient-level characteristics must be interpreted cautiously. Additionally, other differences in treatment approach may contribute to differences in CYP2C19 effect observed between ethic populations. For example, there is trend toward a higher proportion of participants with drug eluting stents in the Asian studies. It is well known that there is substantial variability in clopidogrel pharmacokinetics and pharmacodynamics, even after accounting for known variables, 9 and it is possible that some of this variability is caused by ethnicity-specific genetic factors, geographic-specific nongenetic factors, or epigenetic differences. For example, it may be speculated that genetic variability in alternative metabolic pathways for clopidogrel (eg, CES1, the major inactivation pathway for clopidogrel) may lead to the CYP2C19 pathway playing a more important role in Asian populations. Additionally, despite efforts to minimize the risk of publication bias, we cannot rule out that publication bias has contributed to the differences observed between ethnic populations. Understanding the cause of the differences in CYP2C19 LoF allele effects between ethnic populations will be an important area of future research.
The evidence summarized here relates to the association between genotype and cardiovascular outcomes for individuals using clopidogrel, which limits assessment of clinical utility. 58 The RCT-based evidence to support the clinical utility of genotyping CYP2C19 for individuals undergoing PCI is limited to the retrospective analysis of the CURE, PLATO, and TRITON-TIMI 38 studies. [13] [14] [15] 25 The CURE genetic substudy found no indication that CYP2C19 LoF alleles influence clopidogrel effectiveness, but by guest on July 8, 2017 http://circgenetics.ahajournals.org/ Downloaded from the analysis was limited as only 18% of participants underwent PCI. 13 The invasively managed subset in the PLATO genetic substudy and the TRITON-TIMI 38 genetic substudy provide tentative evidence that the CYP2C19 LoF allele influences clopidogrel effectiveness in the PCI setting. 14, 15, 25 Importantly, there were few participants of Asian origin in any of these trials. Thus, evaluation of the clinical utility of screening Asian populations undergoing PCI for carriage of a CYP2C19 LoF allele is an important direction for future research.
In conclusion, currently available evidence is supportive of the hypothesis that CYP2C19 LoF allele carriage has a greater association with adverse cardiovascular outcomes in Asian populations using clopidogrel after PCI. For clopidogrel indications other than PCI, there is little evidence to support an association between carriage of a CYP2C19 allele and increased risk of adverse cardiovascular outcomes. Studies with predominantly white participants using clopidogrel for PCI report a modest increase in the risk of adverse cardiovascular outcomes associated with CYP2C19 LoF allele carriage, and there is moderate unexplained heterogeneity between studies. Studies in Asian (mainly Chinese and Korean) populations report a consistent and marked increase in the risk of adverse cardiovascular outcomes associated with carriage of a CYP2C19 LoF allele. Further studies are required to evaluate the clinical utility of the CYP2C19 LoF allele for guiding antiplatelet therapy in Asian populations and to ascertain whether the increased effect size of the CYP2C19 LoF allele is directly or indirectly related to ethnicity. 
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CLINICAL PERSPECTIVE
Despite >40 original research studies reporting on the association between carriage of a cytochrome P450 2C19 (CYP2C19) lossof-function allele and adverse clinical outcomes for individuals using clopidogrel, considerable uncertainty still remains regarding the role of routine CYP2C19 genotyping for guiding use of clopidogrel. The most notable issue is the considerable inconsistency in results between studies, which to date has remained unexplained. This meta-analysis reports that the effect of CYP2C19 loss-offunction allele carriage on adverse cardiovascular outcomes differs markedly based on the primary ethnic population of the study population (Asian versus white) and, to a lesser extent, the clopidogrel indication (percutaneous coronary intervention versus other). Specifically, in studies including over 10 000 individuals in Asian populations who used clopidogrel for percutaneous coronary intervention, a clear and substantial effect of carriage of a CYP2C19 loss-of-function allele on major cardiovascular outcomes was noted (relative risk of 1.91 [95% confidence interval, 1.61-2.27]). This compares to a more modest effect in white populations (relative risk of 1.20 [95% confidence interval, 1.10-1.31]; n=19 016). Because >50% of Asians carry the CYP2C19 loss-of-function allele, this greater effect size is potentially of major importance in Asian populations. In white populations, no significant association was apparent for participants using clopidogrel for indications that do not involve percutaneous coronary intervention (eg, medically managed acute coronary syndrome, stable coronary artery disease, atrial fibrillation), but the effect in Asian populations is unknown as no large studies in Asian populations recruited participants with indications not involving percutaneous coronary intervention. Supplemental Table 1 . Summary of studies included in the primary analysis Supplemental Table 2 . Quality-related characteristics for studies included in the primary analysis Supplemental Figure 1 . Association between carriage of one or two CYP2C19 loss-offunction (LoF) alleles and adverse cardiovascular outcomes for individuals using clopidogrel sensitivity analysis including studies with 200 or more participants.
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SUPPLEMENTAL MATERIAL
Supplemental Figure 2 . Association between carriage of one CYP2C19 loss-of-function (LoF) alleles and adverse cardiovascular outcomes for individuals using clopidogrel.
Supplemental Figure 3 . Association between carriage of two CYP2C19 loss-of-function (LoF) alleles and adverse cardiovascular outcomes for individuals using clopidogrel.
Supplemental Figure 4 . Association between carriage of one or two CYP2C19 loss-offunction (LoF) alleles and adverse cardiovascular outcomes for individuals using clopidogrel exploratory analysis of specific Asian ethnicities.
Supplemental Figure 5 . Association between carriage of one or two CYP2C19 loss-offunction (LoF) alleles and adverse cardiovascular outcomes for individuals using clopidogrel exploratory analysis of allele genotyped.
Supplemental Figure 6 . Association between carriage of one or two CYP2C19 loss-offunction (LoF) alleles and bleeding outcomes for individuals using clopidogrel. Figure 1 . Association between carriage of one or two CYP2C19 lossof-function (LoF) alleles and serious adverse cardiovascular outcomes for individuals using clopidogrelsensitivity analysis including studies with 200 or more participants.
Supplemental Figure 2 . Association between carriage of one CYP2C19 loss-offunction (LoF) allele and adverse cardiovascular outcomes for individuals using clopidogrel.
Analysis restricted to studies of 500 or more participants. Studies were stratified on the basis of predominant participant ethnicity and whether study participants predominantly were using clopidogrel for percutaneous coronary intervention (PCI).
Supplemental Figure 3 . Association between carriage of two CYP2C19 loss-offunction (LoF) alleles and adverse cardiovascular outcomes for individuals using clopidogrel.
Supplemental Figure 4 . Association between carriage of one or two CYP2C19 lossof-function (LoF) alleles and serious adverse cardiovascular outcomes for individuals using clopidogrelexploratory analysis of specific Asian ethnicities.
Studies were restricted to those with predominantly Asian participants and a sample size of 500 or more, and stratified on the basis of specific Asian ethnicity.
Supplemental Figure 5 . Association between carriage of one or two CYP2C19 lossof-function (LoF) alleles and serious adverse cardiovascular outcomes for individuals using clopidogrelexploratory analysis of allele genotyped.
Studies were restricted to those with predominantly Asian participants and a sample size of 500 or more, and stratified on the basis of whether only CYP2C19 *2 alleles were genotyped or both *2 and *3 were genotyped.
